Last reviewed · How we verify
Ovitrelle
At a glance
| Generic name | Ovitrelle |
|---|---|
| Sponsor | Hadassah Medical Organization |
| Target | Lutropin-choriogonadotropic hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Ulcerative colitis
Common side effects
Key clinical trials
- Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (PHASE1, PHASE2)
- INTEnsity of ovariaN Stimulation and Embryo Quality (PHASE4)
- Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study
- Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm (PHASE2)
- Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule (NA)
- Assessment of the Feasibility of Frozen Embryo Transfers in a Natural Cycle Among Obese Compared to Non-Obese Patients
- PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis (PHASE1)
- Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ovitrelle CI brief — competitive landscape report
- Ovitrelle updates RSS · CI watch RSS
- Hadassah Medical Organization portfolio CI